Enteris BioPharma, a 24-person biotech based in Boonton, N.J., last month launched a trial of its oral leuprolide endometriosis therapy, Ovarest.
Ovarest is the company’s most advanced internal candidate and represents Enteris’ attempt to overcome the challenges presented by the oral delivery of peptides, according to CEO Joel Tune.
Get the full story at our sister site, Drug Delivery Business News.
The post Enteris BioPharma launches endometriosis trial with oral peptide delivery tech appeared first on MassDevice.
from MassDevice http://ift.tt/2gJe2bh
Cap comentari:
Publica un comentari a l'entrada